# Claus G. Roehrborn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/claus-g-roehrborn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 47,816 |
| Field | Urinary Bladder and Prostate Research |
| h-index | 112 |
| i10-index | 455 |
| Last Known Institution | Southwestern Medical Center |
| OpenAlex ID | https://openalex.org/A5049019006 |
| ORCID iD | https://orcid.org/0000-0003-4024-7369 |
| Works | 945 |

## Researcher papers

- [The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia](https://scholariq.org/papers/the-long-term-effect-of-doxazosin-finasteride-and-combination-therapy-on-the/)
- [Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia](https://scholariq.org/papers/update-on-aua-guideline-on-the-management-of-benign-prostatic-hyperplasia/)
- [The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia](https://scholariq.org/papers/the-effect-of-finasteride-on-the-risk-of-acute-urinary-retention-and-the-need/)
- [A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra](https://scholariq.org/papers/a-cellular-anatomy-of-the-normal-adult-human-prostate-and-prostatic-urethra/)
- [Tadalafil Administered Once Daily for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Dose Finding Study](https://scholariq.org/papers/tadalafil-administered-once-daily-for-lower-urinary-tract-symptoms-secondary-to/)
- [SERUM PROSTATE SPECIFIC ANTIGEN IS A STRONG PREDICTOR OF FUTURE PROSTATE GROWTH IN MEN WITH BENIGN PROSTATIC HYPERPLASIA](https://scholariq.org/papers/serum-prostate-specific-antigen-is-a-strong-predictor-of-future-prostate-growth/)
- [Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action](https://scholariq.org/papers/tadalafil-for-the-treatment-of-lower-urinary-tract-symptoms-secondary-to-benign/)
- [NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER](https://scholariq.org/papers/nomograms-including-nuclear-matrix-protein-22-for-prediction-of-disease/)

## Researcher topics

- [Urinary Bladder and Prostate Research](https://scholariq.org/topics/urinary-bladder-and-prostate-research-2/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Pelvic floor disorders treatments](https://scholariq.org/topics/pelvic-floor-disorders-treatments/)
- [Hormonal and reproductive studies](https://scholariq.org/topics/hormonal-and-reproductive-studies/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.